12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Melphalan delivered via Delcath's Chemosat system regulatory update

Delcath said FDA accepted an NDA for its chemosaturation system delivering melphalan to treat unresectable metastatic melanoma in the liver. The agency accepted the application and assigned...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >